Bloom Diagnostics has additionally raised $11.7 million Series B funding led by Thomas Pfisterer from WILD Group

Bloom Diagnostics, a Zurich, Switzerland-based provider of home-test-kit designed to perform a blood test at home, announced that it recently closed a €10M ($11.8M) million Series B funding round.

The funding was closed in May 2020 and it was led by Thomas Pfisterer from WILD Group.

The proceeds from the round will be used for additional R&D and to drive expansion throughout Europe and the US. Among their early investors are Speedinvest from Austria and Canadian Walter Group.

Bloom Diagnostics, founded in 2014 by Angelica Kohlmann and Thomas Kupper, developed a product called  the Bloom System, aiming to impact the healthcare market by making smart testing accessible to everyone. The product is backed by a smart diagnostic system that can be used for a wide range of medical conditions.